- Patent Title: Chemically modified single-stranded RNA-editing oligonucleotides
-
Application No.: US16329787Application Date: 2017-08-31
-
Publication No.: US10941402B2Publication Date: 2021-03-09
- Inventor: Janne Juha Turunen , Antti Aalto , Bart Klein , Lenka Van Sint Fiet , Julien Auguste Germain Boudet
- Applicant: ProQR Therapeutics II B.V.
- Applicant Address: NL Leiden
- Assignee: ProQR Therapeutics II B.V.
- Current Assignee: ProQR Therapeutics II B.V.
- Current Assignee Address: NL Leiden
- Agency: Goodwin Procter LLP
- Priority: GB1614858 20160901,GB1616374 20160927,GB1621467 20161216,GB1703034 20170224,GB1707508 20170510
- International Application: PCT/EP2017/071912 WO 20170831
- International Announcement: WO2018/041973 WO 20180308
- Main IPC: C12N15/113
- IPC: C12N15/113

Abstract:
The invention relates to antisense oligonucleotides that are capable of bringing about specific editing of a target nucleotide (adenosine) in a target RNA sequence in a eukaryotic cell, wherein said oligonucleotide does not, in itself, form an intramolecular hairpin or stem-loop structure, and wherein said oligonucleotide comprises a non-complementary nucleotide in a position opposite to the nucleotide to be edited in the target RNA sequence.
Public/Granted literature
- US20190218552A1 CHEMICALLY MODIFIED SINGLE-STRANDED RNA-EDITING OLIGONUCLEOTIDES Public/Granted day:2019-07-18
Information query
IPC分类: